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Abstract
Background: The measurement of serum thyroglo-
bulin (Tg) is widely used as a marker for recurrence
of thyroid carcinoma following total thyroidectomy.
However, this method cannot differentiate between
benign and malignant disease. We focused on the
sugar chain in the Tg molecule and investigated the
usefulness of Lens culinaris agglutinin (LCA)-reactive
Tg ratios in sera and wash fluids obtained during fine-
needle aspiration (FNA) for the detection of thyroid
carcinoma.
Methods: The study was performed using 203 serum
samples (115 from patients with benign thyroid dis-
ease and 88 from patients with thyroid carcinomas)
and 176 wash fluid samples (143 benign, 21 malig-
nant, and 12 inconclusive). LCA-reactive Tg ratios
were determined using an enzyme-linked immuno-
sorbent assay, and a comparison was made between
malignant and benign lesions.
Results: In serum, the ratio in patients with malignan-
cy was 79.5"6.0 wmean"standard deviation (SD)x,
significantly lower than in patients with benign
lesions (84.9"3.5). The ratios in wash fluid from
malignant lesions (75.8"18.9) were also significantly
lower than those from benign lesions (85.6"3.9).
Conclusions: These results suggest that this method
could distinguish between benign and malignant
lesions and may be useful for screening serum and
wash samples.
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Introduction
Measurement of serum thyroglobulin (Tg), thyroid
ultrasonography and fine-needle aspiration (FNA)
cytology are widely used diagnostic methods to
detect thyroid carcinoma (1, 2). Although measure-
ment of the serum Tg concentration is suitable for
screening to detect recurrence or for follow-up follow-
ing surgery for carcinoma surgery (3–6), Tg concen-
trations may be increased even in benign thyroid
diseases. The current method cannot differentiate
between benign and malignant disease. Thus, meas-
urement of serum Tg concentrations is not suitable
for screening to detect primary thyroid carcinoma
(7–9). Even with use of ultrasonography, cases show-
ing atypical findings cannot be diagnosed definitively
(10, 11). In addition, some cases may be difficult to
differentiate, even with use of FNA cytology due to
insufficient amounts of sample (12–14). Differentia-
tion between thyroid follicular carcinoma and folli-
cular adenoma is difficult, even with use of cytology
(15–17).
Although a method for a differential diagnosis of
malignancy based on the identification of specific
genes has been reported (18, 19), it has not yet been
applied clinically. It is difficult to differentiate benign
and malignant tumors based on Tg concentrations,
and there are few methods for the management
of large numbers of these types of samples in the
laboratory (20).
In the present study, we focused on the occurrence
of changes in the sugar chain in the Tg molecule dur-
ing the transformation of thyroid cells into cancer
cells. We developed a new method using enzyme-
linked immunosorbent assay (ELISA) to identify dif-
ferences in the sugar chain by reactivity with lectin.
We investigated whether this method could be used
as a screening method for primary thyroid carcinoma,
using a large number of serum or wash fluid samples
obtained during FNA.
Materials and methods
Clinical materials
This study, as well as the use of all clinical materials
described below, was approved by the individual Institution-
al Ethical Committees. The investigation conformed to the
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Figure 1 The theory of measurement method of LCA-reac-
tive Tg ratio, using ELISA.
This method used the property of LCA lectin that inhibits
anti-Tg monoclonal antibody reaction. Total Tg concentra-
tion and LCA-non-reactive Tg concentration were measured,
and the LCA-reactive Tg ratio (%) was calculated. N-Tg, nor-
mal Tg; M-Tg, Tg from malignant tissue.
guidelines for the handling of animals from the Research
Committees of Kagawa Prefectural College.
This study was performed using 49 thyroid tissue samples
(18 cases of papillary carcinoma, 6 follicular carcinoma, 11
benign follicular adenoma, 7 adenomatous goiter, 1 ana-
plastic carcinoma, and 6 Graves disease), obtained during
surgery at the Department of Surgery II of Shinshu Univer-
sity, and 203 serum samples (115 from patients with benign
thyroid disease, 88 from patients with thyroid carcinoma
including 83 with papillary carcinoma and 5 with follic-
ular carcinoma). We also used 176 wash fluid samples (143
diagnosed as benign, 21 malignant, and 12 inconclusive)
obtained during FNA from the same department and from
Azumi General Hospital which is associated with Shinshu
University. To obtain wash fluid, we performed aspiration
of cells under ultrasonographic guidance. After the cells
were placed onto slides, the wash fluid from the puncture
needle was used. Tissue samples were cryopreserved until
use. Informed consent was obtained from all patients.
Confirmation of changes in Tg sugar chains
in thyroid tissues
Tissue samples from 18 patients with papillary carcinoma,
six with follicular carcinoma, one with anaplastic carcinoma,
11 from patients with benign follicular adenoma, seven with
adenomatous goiter, and from six patients with Graves dis-
ease were soaked in 0.1 mol/L phosphate-buffered saline (pH
7.2, 1 mmol/L phenylmethylsulfonyl fluoride). The samples
were homogenized and centrifuged at 10,000=g for 30 min.
The supernatant was separated with an ACA34 column to
obtain a crude solution of Tg. The optical density of the pro-
tein concentration was measured at 280 nm.
The Tg was isolated with sodium dodecylsulfate poly-
acrylamide gel electrophoresis (SDS-PAGE), transferred onto
a nitrocellulose membrane and allowed to react with labeled
Lens culinaris agglutinin (LCA)-horseradish peroxidase
(HRP) conjugate, HRP-LCA (J-OIL MILLS, Kanagawa, Japan)
to investigate whether there was any difference in the affinity
of Tg derived from each tissue sample.
Reaction with anti-Tg monoclonal antibody (TgMAb) was
performed to confirm that the isolate was indeed Tg. We also
used an alternate method to investigate abnormalities in Tg
sugar chains in carcinomas and benign tumors. Tg from
each tissue was isolated with use of V8 protease (Staphylo-
coccus aureus V8; Sigma, St. Louis, MO, USA), subjected to
SDS-PAGE, transferred onto a nitrocellulose membrane, and
allowed to react with labeled lectin or labeled TgMAb.
Preparation of TgMAb
Using Tg obtained from Graves disease tissues as an anti-
gen, a solution mixed with Freund’s complete adjuvant
(Wako Pure Chemical Industries, Osaka, Japan) at a ratio
of 1:9 was administered intraperitoneally to BALB/c mice
(Charles River Laboratories Japan, Inc., Shiga, Japan) at a
dose of 80 mg/mouse. After confirmation of an increase in
anti-Tg antibody titers, cell fusion between mouse spleen
lymphocytes and P3U1 cells (Wako Pure Chemical Indus-
tries, Osaka, Japan) was performed using the method
described previously to obtain a target clone. The antibody
titer was confirmed by ELISA using labeled antibody isolated
in our laboratory. The TgMAb that was produced was react-
ed with standard Tg solution to confirm recognition of Tg.
Measurement of LCA-reactive Tg ratio in serum
Measurement of LCA-reactive Tg ratio was performed using
ELISA, as shown in Figure 1. LCA reacts with normal Tg
(N-Tg). Thus, HRP-labeled TgMAb cannot react with Tg-LCA
complex. However, LCA cannot react with Tg frommalignant
tissue (M-Tg); HRP-labeled TgMAb reacts with M-Tg.
To measure the LCA-reactive Tg ratio in the 203 serum
samples from patients with thyroid disease (benign in 115
cases, malignant in 88) using ELISA, we coated immuno-
plates with TgMAb isolated in our laboratory (Nalge Nunc
International K.K., Roskilde, Denmark). Aliquots of 50 mL
from each serum sample were added to these plates and
allowed to react at room temperature for 1 h. These were
then washed and 100 mL of LCA lectin (J-OIL MILLS, Kana-
gawa, Japan) diluted 1000-fold with buffer, or buffer alone
as a negative control, was added.
The mixtures were allowed to react overnight at 378C.
They were then washed and 100 mL of HRP-labeled anti-
TgMAb solution (prepared by the method described above)
was added, allowed to react for 1 h, developed with 100 mL
of substrate w3,39,5,59-tetramethylbenzidine (TMB); Kierke-
gaard & Perry Laboratories, Inc, Gaithersburg, MD, USAx,
and measured using a microplate reader. The LCA-reactive
Tg ratio was calculated according to the following equation:
LCA-reactive Tg ratio (%)s
(Total Tg concentrationy
LCA-non-reactive
Tg concentration)
=100
Total Tg concentration
For comparison, Tg concentrations in all serum samples
were measured by the current method.
Measurement of LCA-reactive Tg ratio
in wash fluid
Using the 176 samples of wash fluid (benign in 143 cases,
malignant in 21, inconclusive in 12), measurements were
performed using ELISA, in a manner similar to that de-
scribed for serum, to determine the LCA-reactive Tg ratio (%).
FNAs of tumor were performed at two different times in
the same patient from 18 randomly selected cases to deter-
mine the reproducibility of the LCA-reactive Tg ratio. The
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Figure 2 Immunoblotting of crude Tg solution.
(A) LCA-lectin blotting; (B) TgAb blotting. The range of – indi-
cates no staining; " indicates slight staining; q indicates
weak staining; 2q indicates moderately strong staining; and
3q indicates strong staining. M, marker; Nos. 1, 6: papillary
carcinoma; Nos. 2, 8, and 9: follicular carcinoma; No. 3:
Graves disease; No. 4: normal; No. 5: adenomatous goiter;
No. 7: follicular adenoma.
Table 1 Summary of immunoblotting results.
Clinical Histological type Stain pattern
diagnosis
n – " q 2q 3q
Benign Graves disease 6 – – 1 – 5
Follicular adenoma 11 – – – 1 10
Adenomatous goiter 7 – – – 1 6
Malignant Papillary carcinoma 18 3 6 9 – –
Follicular carcinoma 6 1 1 3 1 –
Anaplastic carcinoma 1 1 – – – –
Staining pattern of crude Tg solution reacting with labeled lectin was classified as – to 3q. The carcinoma group show-
ed staining in the range of – to 2q, whereas the benign group showed strong staining in the range of q to 3q. The range
of – indicates no staining; " indicates slight staining; q indicates weak staining; 2q indicates moderately strong staining;
and 3q indicates strong staining.
time period between the first and second FNA was about 1
month.
Statistical methods
The significance of differences was examined using Stu-
dent’s t-test. p-0.01 were considered to be statistically
significant.
Results
Alteration of Tg sugar chain in thyroid tissues
We used four types of lectins (LCA, concanavalin A,
ricinus communis agglutinin-120, and datura stra-
monium agglutinin) to investigate which types of
lectins could detect a significant difference between
benign and malignant disease. LCA binding to Tg in
malignant disease was significantly lower than in
benign disease (data not shown). Thus, we used this
lectin.
Immunoblotting of crude Tg solution and labeled
lectin LCA in each thyroid tissue specimen demon-
strated strong staining for Tg sugar chains in the
group with benign tumors and those with Graves dis-
ease. Weak staining was observed in patients with
papillary carcinoma.
After Tg was digested with use of V8 protease,
immunoblotting was performed as described above.
Carcinoma tissue showed diverse patterns, from
weak to slightly stronger bands with LCA staining.
All tissues from those with benign tumors and Graves
tissues showed strong bands (Figure 2A).
In Figure 2A, M means marker; Nos. 1 and 6 are
papillary carcinomas; Nos. 2, 8, and 9 are follicular
carcinomas; No. 3 is Graves’ disease; No. 4 is normal;
No. 5 is adenomatous goiter; and No. 7 is follicular
adenoma. The benign group tended to show strong
staining, and the malignant group tended to show
weak staining.
Figure 2B showed anti-Tg antibody (TgAb) blotting.
Nos. 6 and 8 showed strong staining in the TgAb blot
and no staining in LCA-lectin blot. Thus, there was an
apparent difference in immunoblotting results of the
sugar chains in Tg molecules in tissues from patients
with carcinoma and those with benign tumors.
Table 1 shows a summary of the immunoblotting
results. The group with malignant disease showed
staining in the range of – to 2q, whereas the benign
group showed strong staining in the range of q to
3q. The range of – indicates no staining, examples
include Nos. 6 and 8 in Figure 2A; "means slight
staining, such as No. 1 in Figure 2A;q indicates weak
staining, examples include Nos. 3 and 9 in Figure 2A;
2q indicates moderately strong staining, such as No.
2 in Figure 2A; and 3q indicates strong staining, such
as Nos. 4, 5, and 7 in Figure 2A.
Measurement of LCA-reactive Tg ratio in serum
Samples from patients with benign (115 cases) and
malignant disease (88 cases) were examined individ-
ually to determine the LCA-reactive Tg ratio in serum
using ELISA.
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Figure 3 Distribution of LCA-reactive Tg ratios in sera.
The LCA-reactive Tg ratio in benign cases was 84.9"3.5
(mean"SD), and in malignant cases was 79.5"6.0
(mean"SD).
Figure 4 Total Tg concentration in sera.
Tg concentration in sera was measured using the current
method. There was no significant difference between the
benign and the malignant group.
Table 2 Relationship between the LCA-reactive Tg ratio in sera and clinical diagnosis.
Clinical diagnosis n Positive % Negative %
Benign 115 13 11.3 102 88.7
Malignant 88 54 61.4 34 38.6
When an LCA-reactive Tg ratio of 81.8% was used as the cut-off threshold, with cases below this level defined as positive,
the positive rate tended to be higher in the malignant group (61.4%) than in the benign group (11.3%).
In comparison with the benign group, themalignant
group showed a significantly lower ratio of LCA-reac-
tive Tg wbenign: mean"standard deviation (SD);
84.9"3.5, malignant: mean"SD; 79.5"6.0, p-0.001x
(Figure 3).
When an LCA-reactive Tg ratio of 81.8% was used
as the cut-off threshold, with patients below this level
defined as positive, the rate of positivity was 11.3%
in the benign group and 61.4% in the malignant group
(Table 2).
For comparison, Tg concentrations in serum sam-
ples were measured by the current method. There
was no significant difference between the malignant
group and the benign group (Figure 4).
Measurement of LCA-reactive Tg ratio
in wash fluid
Three groups of wash fluid samples (143 benign, 21
malignant, and 12 inconclusive) were examined indi-
vidually to determine the LCA-reactive Tg ratio using
ELISA.
As shown in Figure 5, in comparison with the
benign group, the malignant group showed a signi-
ficantly lower ratio of LCA-reactive Tg (benign:
mean"SD; 85.6"3.9; malignant: mean"SD; 75.8"
18.9, p-0.001). Comparing the benign and inconclu-
sive groups, the latter showed a significantly lower
ratio (inconclusive: mean"SD; 78.0"19.4, p-0.001).
However, there was no significant difference between
the groups with malignant and inconclusive disease.
When an LCA-reactive Tg ratio of 80% was used as
the cut-off threshold, with cases below this level
defined as positive, the rate of positivity was 42.9%
in the malignant group, while 93.7% of patients in
the benign group were negative (Table 3).
Inconclusive cases, such as those with follicular
tumor, tended to demonstrate low ratios of LCA-reac-
tive Tg. This finding indicated that follicular carcinoma
cases, which cannot be diagnosed by ultra-
sonography and cytological diagnosis, may be includ-
ed in this group.
Reproducibility of LCA-reactive Tg ratio
by multiple FNAs
In the 18 cases that underwent FNA of the tumor at
two different times, approximately similar levels were
shown on the two tests (Table 4). Reproducibility of
the examination was thus confirmed.
Discussion
It has been reported that total Tg concentration in
serum cannot distinguish between benign and malig-
nant thyroid disease. We used LCA lectin and exam-
ined the variations in the sugar chains of Tg from
sera and wash fluids. We confirmed that the LCA-
reactive Tg ratio could distinguish between thyroid
carcinoma and benign thyroid tumor.
Tg is a protein required for synthesis of thyroid
hormone and is expressed specifically in the thyroid.
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Figure 5 Distribution of LCA-reactive Tg ratios in washout
fluids.
The LCA-reactive Tg ratio in benign lesions was 85.6"
3.9 (mean"SD), and in malignant lesions was 75.8"18.9
(mean"SD). In inconclusive cases, the ratio was 78.0"
19.4 (mean"SD).
Table 4 Reproducibility of LCA-reactive Tg ratio by multiple
FNAs.
Case LCA-reactive Tg ratio
First, % Second, % Difference
1 88.9 88.4 0.5
2 85.2 85.2 0
3 12.8 19.9 7.1
4 87.3 83.5 3.8
5 85.6 85.5 0.1
6 85.4 88.1 2.7
7 86.4 88.5 2.1
8 87.3 86.6 0.7
9 85.7 82.9 2.8
10 88.9 87.2 1.7
11 88.0 86.4 1.6
12 86.3 85.9 0.4
13 87.1 87.8 0.7
14 88.3 88.2 0.1
15 82.2 86.1 3.9
16 86.5 85.3 1.2
17 85.3 89.2 3.9
18 81.0 81.9 0.9
FNA was performed twice on the same tumor in 18 cases.
These cases showed approximately the same levels on
repeat examination, confirming the reproducibility of the
examination.
Table 3 Relationship between LCA-reactive Tg ratio in wash fluid and clinical diagnosis.
Clinical diagnosis n Positive % Negative %
Benign 143 9 6.3 134 93.7
Malignant 21 9 42.9 12 57.1
When an LCA-reactive Tg ratio of 80% was used as the cut-off threshold, with cases below this level defined as positive, the
positive rate tended to be higher in the malignant group (42.9%) than in the benign group (6.3%).
It consists of two subunits with a molecular weight
of 330,000. Tg is also known to contain 10% sugar
chains (21–23). The sugar chains change in parallel
with malignant alterations in the cells. In particular,
the structure of the sugar chain of Tg produced by
carcinoma cells changes considerably (24). Although
there are two branches in normal cells, three to five
branches are seen in carcinoma. In carcinoma, the
sugar type is also known to change from a high man-
nose-dominant type to a mixed or Gal-GlcNac type
(25). This study suggests that LCA reactivity could
distingish between these variations in the sugar
chain. LCA can react with N-Tg sugar chains from
benign lesions, but not with varied sugar chains of Tg
from patients with thyroid carcinoma. Moreover, the
influence of autoantibody, detected in patients with
chronic thyroiditis, is small because this method util-
ized the ratio.
Although lectin blotting of LCA showed a dramatic
change between benign disease and malignancy,
the data from ELISA using LCA was not dramatically
changed. The reason for the discrepancy is presumed
to be as follows. Lectin blotting of LCA was used for
tumor tissues obtained during surgery. Thus, the data
reflect the alterations in Tg sugar chains from tumor
lesions only. Lectin blotting of LCA showed a dra-
matic change between benign disease and malignan-
cy. However, ELISA with LCA used sera and wash
fluids obtained during FNA. The serum contains Tg
from benign or malignant lesions and from normal
thyroid tissue. The data showed a ratio of Tg from
lesion to total Tg; thus, it was not different. Wash fluid
may also contain N-Tg because the aspiration needle
passes through normal thyroid tissue.
We consider that the LCA-reactive Tg ratio has pos-
sible utility as a specific marker of thyroid carcinoma.
This method has the following advantages:
1. Both the serum and wash fluid can be used as
samples.
2. A differential diagnosis between malignant and
benign lesions can be expressed as a numerical
value, and does not rely on individual evaluations.
Consequently, this allows for a more objective
evaluation.
3. A great many cases can be examined simultane-
ously, making this method available for screening
examinations.
4. This method is effective for cases where ultrasono-
graphy and cytological diagnosis are inconclusive.
However, diagnosis is difficult if the amount of
Tg collected is small (5 ng/mL or less).
In conclusion, we developed a new method for
the diagnosis of alterations in the sugar chains of Tg
molecules, using the reactive ratio of LCA lectin. This
method may be useful for distinguishing between
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thyroid carcinoma and benign thyroid tumor. Either
serum or wash fluid may be used in this method
for the screening of primary thyroid carcinoma.
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